• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Praxis Precision Medicines, Inc. - Common Stock (NQ:PRAX)

    320.48 +0.94 (+0.29%)
    Streaming Delayed Price Updated: 4:00 PM EST, Feb 10, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Praxis Precision Medicines, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    News headline image
    Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    The Biotech Renaissance: Scientific Breakthroughs and M&A Frenzy Spark a New Bull Market
    The U.S. biotech sector has officially entered a new golden age. As of January 22, 2026, the industry is witnessing a "renaissance" that has effectively erased the memories of the grueling three-year... 
    Via MarketMinute
    Topics Artificial Intelligence ETFs Initial Public Offering
    News headline image
    Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines, Inc. Announces Proposed Public Offering
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Why Praxis Precision Medicines Stock Popped Today ↗
    A medical breakthrough is shining a light on the biotech's promising development platform. 
    Via The Motley Fool
    News headline image
    Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal
    The biopharmaceutical sector witnessed a dramatic surge in volatility today, December 29, 2025, as the industry careened toward the end of its strongest year in two decades. In a day defined by extreme... 
    Via MarketMinute
    Topics ETFs Intellectual Property
    News headline image
    Praxis Stock Surges On FDA Breakthrough Status For Essential Tremor Drug ↗
    Praxis Precision Medicines Inc (NASDAQ: PRAX) stock rose after FDA granted BTD for ulixacaltamide to treat essential tremor. 
    Via Benzinga
    News headline image
    Traders are paying attention to the gapping stocks in Monday's session. ↗
    There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday. 
    Via Chartmill
    News headline image
    Why Did Praxis Precision Stock Surge 12% Pre-Market Today? ↗
    The Breakthrough Therapy Designation designation for ulixacaltamide was granted after positive topline results from the Essential3 program, which included two Phase 3 studies. 
    Via Stocktwits
    News headline image
    Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026
    EMBOLD data to serve as basis of efficacy and safety following discussion with the FDA 
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines Announces Alignment with FDA on Simplified and Accelerated Registrational Pathway for Elsunersen in Early Onset SCN2A Developmental and Epileptic Encephalopathy
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis AES Wrap-up: Best-in-Class Potential Across Rare Pediatric and Adult Epilepsies
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    What's going on in today's session ↗
    Wondering how the US markets performed one hour before the close of the markets on Friday? Discover the movers and shakers of today's session in our comprehensive analysis. 
    Via Chartmill
    News headline image
    Top movers analysis in the middle of the day on 2025-12-05: top gainers and losers in today's session. ↗
    Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements. 
    Via Chartmill
    News headline image
    The market is filled with gapping stocks in Friday's session. ↗
    Let's have a look at what is happening on the US markets on Friday. Below you can find the gap up and gap down stocks in today's session. 
    Via Chartmill
    News headline image
    What's going on in today's pre-market session ↗
    Before the opening bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
    Via Chartmill
    News headline image
    Why Did PRAX Stock Rocket 24% Pre-Market Today? ↗
    The Data Monitoring Committee (DMC) recommended stopping the EMBOLD study ahead of schedule after the interim analysis demonstrated strong positive outcomes. 
    Via Stocktwits
    News headline image
    Praxis Precision Medicines Stock Surges 25% In Friday Pre-Market Trading— What&#39;s Going On? ↗
    Praxis Precision Medicines Inc. (NASDAQ: PRAX) shares surged 24.81% in pre-market trading on Friday, climbing to $237.10— what's going on? 
    Via Benzinga
    News headline image
    Nasdaq, S&P 500 Futures Set For Firm Open Ahead Of PCE Inflation Data: Why NFLX, SMX, SOFI, IOT Are On Traders' Radar ↗
    Retail sentiment, however, remains cautious, with SPY and QQQ flashing bearish on Stocktwits. 
    Via Stocktwits
    Topics Artificial Intelligence ETFs Economy
    News headline image
    Curious about the stocks that are showing activity after the closing bell on Thursday? ↗
    As the regular session of the US market concludes on Thursday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
    Via Chartmill
    News headline image
    Praxis Precision Medicines Announces Positive Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines Announces Positive Pre-NDA Meeting with FDA for Ulixacaltamide in Essential Tremor
    Praxis confirms plans to submit the essential tremor NDA for ulixacaltamide in early 2026 
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis to present latest preclinical and clinical advancements across leading epilepsy portfolio at the 2025 American Epilepsy Society (AES) Annual Meeting
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.